Why Akari Therapeutics, Plc’s (AKTX) Stock Is Up 6.60%
As of Wednesday, April 01, Akari Therapeutics, Plc’s AKTX share price has surged by 6.60%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Commentary & Analysis
Is Akari Therapeutics PLC (ADR) (AKTX) Stock a Good Investment?
Learn more about Akari Therapeutics PLC (ADR)'s (AKTX) stock grades for Momentum and Growth and determine whether this Biotechnology & Medical Research stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | AKTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $13.8 | $252.6 | 8% |
|
| Shares Out (Mil) | 1.5 | 52.3 | 6% |
|
| Institutional Ownership | na | 92.1% | na |
|
| Float (Mil) | na | 40.2 | na |
|
| Beta | 0.65 | 0.95 | 38% |
|
| Avg Daily Volume (000s) | 38 | 455 | 26% |
|
| Price Change (52-week) |
(80.6%) | 52.9% | 6% |
|
| Growth | AKTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (0.2%) | (9.9%) | 39% |
|
| EPS (5yr) | 51.9% | 16.0% | 93 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (57.0%) | (15.6%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($1.040) | ($8.010) | ($1.280) | |
| Month Ago EPS | na | na | na | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($2.800) | ($12.000) | ($14.000) | |
| Year/Year Chg | (89.3%) | (61.0%) | (91.6%) | |
| Financials | AKTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($28) | ($43) | 21% |
|
| EPS (TTM) | ($26.914) | ($1.600) | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($11) | ($31) | 19% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $19 | $180 | 10% |
|
| Valuation | AKTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.63 | 2.56 | 12% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | AKTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (66.1%) | (49.8%) | 9% |
|
| ROE | (155.3%) | (55.5%) | 6% |
|
| Liabilities to Assets | 57.6% | 30.3% | 51% |
|
| F-Score | 3 | 3 | 19% |
|
Akari Therapeutics, Plc did not pass any screens on 7/31/2026.
